85 Research Participant jobs in Singapore

We are currently seeking clinicians to fill a Medical Research Doctor role.
You will work with our Global team of research and clinical professionals to facilitate the translation of research data and quality improvement programs into clinical practice and improvement of patient care. The role includes assisting with drafting and reviewing documentation and publications, project coordination and liaison with project teams, as well as presentation to external stakeholders and conference participation.
This is a fantastic opportunity to become involved in medical management and quality improvement projects with an internationally recognised research organisation.
This role offers home-based working from Singapore or hybrid working from our offices in Cambridge and Norwich, UK, on a full or part-time basis, with flexible working hours that can fit alongside caring arrangements or other clinical/research commitments.
Primary Responsibilities
To contribute to medical quality improvement programs.
To continually assess the benefit of our quality improvement programs to patients, and tailor the programs to maximise their real-life application in a clinical setting.
Review and contribute to scientific documents and publications (including proposals and reports).
To independently develop ethics applications for projects.
To contribute to new and existing projects with respect to considering practical medical issues and clinical application; and to understand EMR data and coding systems and give guidance on the application of data to projects.
Review and complete presentations, abstracts, and posters.
Communication and liaison with internal teams across various global locations.
Liaison with study sponsors and steering committee experts.
Presentations and calls with external stakeholders.
Participation and presentations at international medical/scientific conferences.
Qualifications
Doctor of medicine.
Minimum of 3 years of clinical experience ideally gained within the UK.
Clinical experience or scientific study in the field of respiratory medicine is an advantage.
Experience and Key Skills
UK clinical experience is preferred, ideally within NHS Primary Care.
An interest in research and scientific studies.
Experience in scientific writing, publication of peer-review journal publications is preferred.
Client relations, liaising with external parties internationally, strong leadership and presentation skills.
Excellent written and verbal English communication skills.
Salary
is dependent on experience.
Contact Us
Please send your CV with a covering letter summarising your suitability for the role to All candidates will be required to undertake a remote skills test prior to interview. We look forward to hearing from you.
#J-18808-Ljbffr

Leveraging a diverse suite of platforms, Hilleman can rapidly respond to emerging needs to provide the right solution to control the impact of infections. Find out how we use these platforms in our R&D and manufacturing hub in Singapore

Targeted use of microbial species such as E. coli and P. pastoris as high productivity expression platforms, with a view to reducing cost of production.

Deploying cost-effective platforms for the production of various types of vaccines such as live-virus vector, attenuated, and inactivated vaccines.

Development of potential targets using the vesicular stomatitis virus (VSV) and measles virus vectors (MeV), both of which are established as stable and highly reliable platforms.

Using circular RNA as a vaccine modality could potentially offer greater biostability, thermostability and better immune responses with longer protective responses.

Leveraging polysaccharide conjugation to develop more effective vaccines which may be a safer alternative.

Leveraging a diverse suite of platforms, Hilleman can rapidly respond to emerging needs to provide the right solution to control the impact of infections. Find out how we use these platforms in our R&D and manufacturing hub in Singapore
Microbial
Targeted use of microbial species such as E. coli and P. pastoris as high productivity expression platforms, with a view to reducing cost of production.
Deploying cost-effective platforms for the production of various types of vaccines such as live-virus vector, attenuated, and inactivated vaccines.
Live Viral Vectors
Development of potential targets using the vesicular stomatitis virus (VSV) and measles virus vectors (MeV), both of which are established as stable and highly reliable platforms.
RNA-based Platform
Using circular RNA as a vaccine modality could potentially offer greater biostability, thermostability and better immune responses with longer protective responses.
Leveraging polysaccharide conjugation to develop more effective vaccines which may be a safer alternative.
#J-18808-Ljbffr

Hilleman Laboratories operates a first-of-its-kind vaccine development hub in Singapore, consisting of a research and development (R&D) facility at Biopolis, alongside a 30,000 square foot pilot-scale manufacturing facility at 138 Depot Road. The hub provides end-to-end product development solutions from concept to pilot manufacturing and Phase II clinical studies, supporting the development of affordable, high-value vaccines and biologics for low- and middle-income countries.

The state-of-the-art R&D facility in Biopolis undertakes process development, analytical development, drug product development and formulation for vaccines and biologics. It focuses on product development of vaccines and biologics, including candidate selection, design, early manufacturing process development and preclinical studies.

As one of the facilities of the dual-feature set up, the Good Manufacturing Practices (GMP) facility is capable of producing clinical trial material (up to Phase II) and is equipped with drug product fill-&-finish capability. This unique set-up enables the two facilities working in tandem to provide end-to-end product development, leveraging innovative technology platforms to develop affordable, high-value vaccines and biologics. The facility has also been designed to easily pivot to manufacture vaccines for emergency use during pandemics.

Hilleman is a critical connector, bringing together health ecosystem stakeholders for vaccines and biologics R&D and manufacturing. We collaborate with local, regional and global partners and stakeholders, including policymakers and governments, to facilitate wider, affordable access to life-saving vaccines and biologics. Apart from conducting translational research and product development, we also act as a catalyst for advancements in the biopharma industry by facilitating technology transfers, and capability building through manpower development initiatives.

Hilleman Laboratories operates a first-of-its-kind vaccine development hub in Singapore, consisting of a research and development (R&D) facility at Biopolis, alongside a 30,000 square foot pilot-scale manufacturing facility at 138 Depot Road. The hub provides end-to-end product development solutions from concept to pilot manufacturing and Phase II clinical studies, supporting the development of affordable, high-value vaccines and biologics for low- and middle-income countries.

Research and Development

The state-of-the-art R&D facility in Biopolis undertakes process development, analytical development, drug product development and formulation for vaccines and biologics. It focuses on product development of vaccines and biologics, including candidate selection, design, early manufacturing process development and preclinical studies.

GMP Pilot Manufacturing

As one of the facilities of the dual-feature set up, the Good Manufacturing Practices (GMP) facility is capable of producing clinical trial material (up to Phase II) and is equipped with drug product fill-&-finish capability. This unique set-up enables the two facilities working in tandem to provide end-to-end product development, leveraging innovative technology platforms to develop affordable, high-value vaccines and biologics. The facility has also been designed to easily pivot to manufacture vaccines for emergency use during pandemics.

Partnerships

Hilleman is a critical connector, bringing together health ecosystem stakeholders for vaccines and biologics R&D and manufacturing. We collaborate with local, regional and global partners and stakeholders, including policymakers and governments, to facilitate wider, affordable access to life-saving vaccines and biologics. Apart from conducting translational research and product development, we also act as a catalyst for advancements in the biopharma industry by facilitating technology transfers, and capability building through manpower development initiatives.

We are seeking a Clinical Research Coordinator to oversee the daily operations of clinical trials and ensure compliance with regulatory requirements.